<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00469209</url>
  </required_header>
  <id_info>
    <org_study_id>2005-0893</org_study_id>
    <nct_id>NCT00469209</nct_id>
  </id_info>
  <brief_title>Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients</brief_title>
  <official_title>Phase I/II Study of the Combination of Bortezomib With Arsenic Trioxide, Ascorbic Acid and High-Dose Melphalan for Patients With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cephalon</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objectives:

        1. To evaluate the toxicity and safety of a combination of bortezomib with arsenic
           trioxide, ascorbic acid and high-dose melphalan in patients with multiple myeloma

        2. To evaluate the efficacy of a combination of bortezomib with arsenic trioxide, ascorbic
           acid and high-dose melphalan in patients with multiple myeloma

        3. To determine the effects of bortezomib on melphalan pharmacokinetics
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Melphalan is designed to damage the DNA of cells, which may cause cancer cells to die.
      High-dose melphalan is considered the standard of care for multiple myeloma. Bortezomib is
      designed to block a protein that plays a role in cell function and growth, which may cause
      cancer cells to die. Arsenic trioxide may cause cancer cells to die, and researchers want to
      find out if arsenic trioxide helps melphalan in killing cancer cells. Vitamin C makes arsenic
      trioxide more available inside the cancer cells, and researchers want to learn if Vitamin C
      makes arsenic trioxide more effective.

      Before you can start treatment on this study, you will have &quot;screening tests.&quot; These tests
      will help the doctor decide if you are eligible to take part in this study. You will have a
      physical exam, including measurement of vital signs (blood pressure, heart rate, temperature,
      and breathing rate). Your complete medical history will be recorded. You will have a dental
      exam to check for any infected teeth or gums that may flare up after chemotherapy.

      You will have a bone marrow aspirate and biopsy. To collect a bone marrow aspirate/biopsy, an
      area of the hip or chest bone is numbed with anesthetic, and a small amount of bone marrow is
      withdrawn through a large needle. Cytogenetic tests will be performed on the aspirate sample
      to look for any genetic abnormalities in your DNA. You will have x-rays of your bones taken.
      The study doctor will look at the x-rays to see if there are any myeloma-related bone
      changes. You will also have a chest x-ray.

      You will have blood (about 2 tablespoons) and urine collected for routine tests. You will
      have a pulmonary function test, to check if your lungs are strong enough for high-dose
      chemotherapy. You will have an electrocardiogram (ECG -- a test that measures the electrical
      activity of the heart). You will also have a MUGA scan to evaluate the function of your
      heart. Women who are able to have children must have a negative blood pregnancy test. The
      blood will be drawn as part of the 2 tablespoons drawn at screening.

      If you are found to be eligible to take part in this study, you will be randomly assigned (as
      in the toss of dice) to one of 3 treatment groups. There is an equal chance of being assigned
      to any of the 3 groups. All 3 groups will receive melphalan, arsenic trioxide, and Vitamin C.
      The second and third groups will also receive bortezomib, but at different dose levels. The
      first 3 participants assigned to receive bortezomib on this study will receive the lower of 2
      bortezomib dose levels.

      You will receive arsenic trioxide through a needle in a vein over 2 hours, once a day for 7
      days (Days -9 to -3). At the same time, you will receive Vitamin C once a day through the
      vein for 7 days. After you receive the arsenic trioxide on Days -4 and -3, you will receive
      melphalan through the vein over 30 minutes.

      If you are in Group 2 or 3, you will receive bortezomib by an intravenous (IV) push on Days
      -9, -6, and -3. An IV push takes a short period of time (less than 1 minute).

      You will receive standard inpatient and outpatient stem cell transplant care and testing. You
      will have to sign a separate consent form that describes the transplant procedure and its
      risks. Your stem cells will be reinfused 2 days after the last dose of melphalan. To check
      for any side effects, you will have an ECG performed 14 days after the transplant.

      If intolerable side effects from the chemotherapy occur or there is sign of disease after the
      transplant, you will be taken off study. If you have already received melphalan and side
      effects occur, then the transplant will happen. However, if intolerable side effects develop
      before melphalan, then you may be taken off study without having the transplant. If you are
      taken off study early, you still may need to return for routine post-transplant follow-up
      visits, if your transplant physician decides it is necessary.

      If there is no sign of disease after the transplant, you will have routine follow-up visits.
      Blood (about 2 tablespoons) will be drawn for routine tests at least once a week during the
      first month after the transplant, and then once every month for the next 3 months after that.
      At about 3, 6, and 12 months after the transplant, you will have bone marrow biopsies and
      aspirates performed to check the status of the disease. You will have blood (about 2
      tablespoons) and urine collected for routine tests. At 12 months after the transplant, you
      will have x-rays of your bones taken.

      One (1) year after the transplant, your participation in this study will be over.

      This is an investigational study. Bortezomib, arsenic trioxide, and melphalan are
      commercially available and FDA-approved for use in patients with myeloma. However, their use
      in combination with Vitamin C (also commercially available) is investigational. Up to 60
      patients will take part in this study. All will be enrolled at M. D. Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Reaching Complete Response (CR)</measure>
    <time_frame>Baseline through Day 180, with assessments at Day 90 and Day 180</time_frame>
    <description>Number of participants with CR at Day 180 who had maintained CR for at minimum of 4 weeks, and who had: No monoclonal protein in urine/serum when analyzed by immunofixation electrophoresis; bone marrow normal by morphological examination with &lt;5% plasma cells, &lt;1% aneuploid light chain restricted population by flow cytometry for DNA/cIg; and, while healing of bony lesion is not required, no new lytic lesion should appear. Further compression fracture of spine not considered progressive disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Toxicity</measure>
    <time_frame>Baseline to event occurence (assessed weekly first 30 days)</time_frame>
    <description>The time to patient toxicity of drug combination bortezomib with arsenic trioxide, ascorbic acid and high-dose melphalan defined in days from baseline measure to occurence of adverse events grade 4 (life threatening or disabling) according to National Cancer Institute Common Toxicity Criteria (CTC), version 3.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Myeloma</condition>
  <arm_group>
    <arm_group_label>No Bortezomib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 1: Melphalan 100 mg/m^2 intravenous (IV) days -4,-3 + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bortezomib 1.0 mg/m^2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 2: Bortezomib (Level 1) 1.0 mg/m^2 IV push on Days -9, -6, and -3, Melphalan 100 mg/m^2 IV days -4,-3 + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bortezomib 1.5 mg/m^2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 3: Bortezomib (Level 2) 1.5 mg/m^2 IV push on Days -9, -6, and -3, Melphalan + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trisenox (Arsenic Trioxide)</intervention_name>
    <description>0.25 mg/kg by vein over 2 hours, once a day for 7 days (Days -9 to -3).</description>
    <arm_group_label>No Bortezomib</arm_group_label>
    <arm_group_label>Bortezomib 1.0 mg/m^2</arm_group_label>
    <arm_group_label>Bortezomib 1.5 mg/m^2</arm_group_label>
    <other_name>ATO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Velcade (Bortezomib)</intervention_name>
    <description>Arm 1 (Level 1):
1.0 mg/m^2 intravenous (IV) push on Days -9, -6, and -3. An IV push takes a short period of time (less than 1 minute).
Arm 2 (Level 2):
1.5 mg/m^2 intravenous (IV) push on Days -9, -6, and -3. An IV push takes a short period of time (less than 1 minute).</description>
    <arm_group_label>Bortezomib 1.0 mg/m^2</arm_group_label>
    <arm_group_label>Bortezomib 1.5 mg/m^2</arm_group_label>
    <other_name>PDP-341</other_name>
    <other_name>MLN341</other_name>
    <other_name>PS-341</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>100 mg/m2 by vein days -4,-3, over 30 minutes</description>
    <arm_group_label>No Bortezomib</arm_group_label>
    <arm_group_label>Bortezomib 1.0 mg/m^2</arm_group_label>
    <arm_group_label>Bortezomib 1.5 mg/m^2</arm_group_label>
    <other_name>Alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin C (Ascorbic Acid)</intervention_name>
    <description>1000 mg once a day through the vein for 7 days.</description>
    <arm_group_label>No Bortezomib</arm_group_label>
    <arm_group_label>Bortezomib 1.0 mg/m^2</arm_group_label>
    <arm_group_label>Bortezomib 1.5 mg/m^2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. a) Primary Refractory Disease (defined as failure to achieve even a partial response
             to induction therapy) b) Consolidation of a partial remission (defined as a decrease
             but continued presence of monoclonal protein on serum and urine immunofixation
             electrophoresis, and/or the presence of plasmacytosis on bone marrow aspirate and
             biopsy) c) Relapsing after prior therapy (disease relapsing after achieving a partial
             or complete response to prior conventional or high-dose therapy).

          2. Age up to 75 years.

          3. Zubrod performance status of &lt;2.

          4. Left ventricular ejection fraction &gt;40%. No uncontrolled arrhythmias or symptomatic
             cardiac disease.

          5. Forced expiratory volume (FEV1), forced volume vital capacity (FVC) and Diffusing
             Capacity of the Lung for Carbon Monoxide (DLCO) &gt;40%. No symptomatic pulmonary
             disease.

          6. Serum bilirubin &lt;2 times upper limit of normal, alanine aminotransferase/SGPT &lt;4 times
             upper limit of normal. No evidence of chronic active hepatitis or cirrhosis. No
             effusion or ascites &gt;1L prior to drainage.

          7. HIV-negative.

          8. Negative Beta human chorionic gonadotrophin (hCG) test in a woman with child bearing
             potential, defined as not post-menopausal for 12 months or no previous surgical
             sterilization

          9. Patient or guardian able to sign informed consent

         10. Corrected QT interval less than 470 msec.

        Exclusion Criteria:

          1. Corrected QT interval greater than 470 msec.

          2. Patients in complete remission (defined as the absence of monoclonal protein on serum
             and urine immunofixation electrophoresis, and the absence of plasmacytosis in bone
             marrow aspirate and biopsy).

          3. Patients with non-secretory myeloma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muzaffar H. Qazilbash, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center website</description>
  </link>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2007</study_first_submitted>
  <study_first_submitted_qc>May 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2007</study_first_posted>
  <results_first_submitted>March 23, 2010</results_first_submitted>
  <results_first_submitted_qc>March 22, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 25, 2011</results_first_posted>
  <last_update_submitted>August 1, 2012</last_update_submitted>
  <last_update_submitted_qc>August 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Melphalan</keyword>
  <keyword>Trisenox</keyword>
  <keyword>Arsenic Trioxide</keyword>
  <keyword>Ascorbic Acid</keyword>
  <keyword>Vitamin C</keyword>
  <keyword>Velcade</keyword>
  <keyword>Bortezomib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Arsenic trioxide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Melphalan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period June 2006 to December 2008. All participants recruited at UT MD Anderson Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>No Bortezomib</title>
          <description>Melphalan 100 mg/m^2 intravenous (IV) days -4,-3 + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily</description>
        </group>
        <group group_id="P2">
          <title>Bortezomib 1.0 mg/m^2</title>
          <description>Bortezomib (Level 1) 1.0 mg/m^2 IV push on Days -9, -6, and -3, Melphalan 100 mg/m^2 IV days -4,-3 + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily</description>
        </group>
        <group group_id="P3">
          <title>Bortezomib 1.5 mg/m^2</title>
          <description>Bortezomib (Level 2) 1.5 mg/m^2 IV push on Days -9, -6, and -3, Melphalan + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>No Bortezomib</title>
          <description>Melphalan 100 mg/m^2 intravenous (IV) days -4,-3 + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily</description>
        </group>
        <group group_id="B2">
          <title>Bortezomib 1.0 mg/m^2</title>
          <description>Bortezomib (Level 1) 1.0 mg/m^2 IV push on Days -9, -6, and -3, Melphalan 100 mg/m^2 IV days -4,-3 + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily</description>
        </group>
        <group group_id="B3">
          <title>Bortezomib 1.5 mg/m^2</title>
          <description>Bortezomib (Level 2) 1.5 mg/m^2 IV push on Days -9, -6, and -3, Melphalan + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="20"/>
            <count group_id="B4" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" lower_limit="47" upper_limit="70"/>
                    <measurement group_id="B2" value="59" lower_limit="45" upper_limit="67"/>
                    <measurement group_id="B3" value="64" lower_limit="49" upper_limit="75"/>
                    <measurement group_id="B4" value="60" lower_limit="45" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Reaching Complete Response (CR)</title>
        <description>Number of participants with CR at Day 180 who had maintained CR for at minimum of 4 weeks, and who had: No monoclonal protein in urine/serum when analyzed by immunofixation electrophoresis; bone marrow normal by morphological examination with &lt;5% plasma cells, &lt;1% aneuploid light chain restricted population by flow cytometry for DNA/cIg; and, while healing of bony lesion is not required, no new lytic lesion should appear. Further compression fracture of spine not considered progressive disease.</description>
        <time_frame>Baseline through Day 180, with assessments at Day 90 and Day 180</time_frame>
        <population>Analysis was per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>No Bortezomib</title>
            <description>Melphalan 100 mg/m^2 intravenous (IV) days -4,-3 + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily</description>
          </group>
          <group group_id="O2">
            <title>Bortezomib 1.0 mg/m^2</title>
            <description>Bortezomib (Level 1) 1.0 mg/m^2 IV push on Days -9, -6, and -3, Melphalan 100 mg/m^2 IV days -4,-3 + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily</description>
          </group>
          <group group_id="O3">
            <title>Bortezomib 1.5 mg/m^2</title>
            <description>Bortezomib (Level 2) 1.5 mg/m^2 IV push on Days -9, -6, and -3, Melphalan + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Reaching Complete Response (CR)</title>
          <description>Number of participants with CR at Day 180 who had maintained CR for at minimum of 4 weeks, and who had: No monoclonal protein in urine/serum when analyzed by immunofixation electrophoresis; bone marrow normal by morphological examination with &lt;5% plasma cells, &lt;1% aneuploid light chain restricted population by flow cytometry for DNA/cIg; and, while healing of bony lesion is not required, no new lytic lesion should appear. Further compression fracture of spine not considered progressive disease.</description>
          <population>Analysis was per protocol.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Toxicity</title>
        <description>The time to patient toxicity of drug combination bortezomib with arsenic trioxide, ascorbic acid and high-dose melphalan defined in days from baseline measure to occurence of adverse events grade 4 (life threatening or disabling) according to National Cancer Institute Common Toxicity Criteria (CTC), version 3.</description>
        <time_frame>Baseline to event occurence (assessed weekly first 30 days)</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Study period 2 years.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>No Bortezomib</title>
          <description>Melphalan 100 mg/m^2 intravenous (IV) days -4,-3 + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily</description>
        </group>
        <group group_id="E2">
          <title>Bortezomib 1.0 mg/m^2</title>
          <description>Bortezomib (Level 1) 1.0 mg/m^2 IV push on Days -9, -6, and -3, Melphalan 100 mg/m^2 IV days -4,-3 + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily</description>
        </group>
        <group group_id="E3">
          <title>Bortezomib 1.5 mg/m^2</title>
          <description>Bortezomib (Level 2) 1.5 mg/m^2 IV push on Days -9, -6, and -3, Melphalan + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ventriculat tachycardia/hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>small bowel obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>pneumonitis/death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>acute renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>pulmonary embolus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>mucositis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>low back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>elevated transaminases</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>hydronephrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>pulmonary edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Muzaffar H. Qazilbash, MD</name_or_title>
      <organization>University of Texas M.D. Anderson Cancer Center</organization>
      <phone>713-745-3458</phone>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

